NCT04400058 - Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression | Biotech Hunter

Enrollment

207

Participants

Timeline

Start Date

June 1, 2020

Primary Completion Date

February 1, 2022

Study Completion Date

February 1, 2022

Conditions

Covid-19

Interventions

BIOLOGICAL

Octagam 10%

Octagam 10%, 2 g/kg divided by 4 days (0.5 g/kg/day), administered by intravenous infusion over approximately 2 hours per day over 4 consecutive days

OTHER

Saline Solution

Placebo

Trial Locations (22)

20007

Octapharma Research Site, Washington D.C.

29401

Octapharma Research Site, Charleston

35660

Octapharma Research Site, Sheffield

39623

Octapharma Research Site, Kremenchuk

48670

Octapharma Research Site, Midland

52242

Octapharma Research Site, Iowa City

58701

Octapharma Research Site, Minot

61096

Octapharma Research Site, Kharkiv

70433

Octapharma Research Site, Covington

75708

Octapharma Research Site, Tyler

76007

Octapharma Research Site, Ivano-Frankivsk

89102

Octapharma Research Site, Las Vegas

92123

Octapharma Research Site, San Diego

92354

Octapharma Research Site, Loma Linda

92357

Octapharma Research Site, Loma Linda

92663

Octapharma Research Site, Newport Beach

92868

Octapharma Research Site, Orange

96813

Octapharma Research Site, Honolulu

111539

Octapharma Research Site, Moscow

129301

Octapharma Research Site, Moscow

153025

Octapharma Research Site, Ivanovo

390000

Octapharma Research Site, Ryazan